Medical-grade skincare brand ZO Skin Health launched a new peptide concentrate, specifically suited for post-treatment care. The Peptide Facial Refining Concentrate, a serum that complements neurotoxins and dermal fillers treatments between visits, will be available for patients at ZO provider offices as of Sept. 16.
Looking closer at the formula’s ingredients, the concentrated serum features four peptide technologies that target signs of aging and support the skin's underlying architecture, per a Sept. 16 press release. Within the concentrate, the Zploy Complex completes the new formula, helping soothe redness and support the skin's protective barrier.
This article is only available to registered users.
Log In to View the Full Article
Medical-grade skincare brand ZO Skin Health launched a new peptide concentrate, specifically suited for post-treatment care. The Peptide Facial Refining Concentrate, a serum that complements neurotoxins and dermal fillers treatments between visits, will be available for patients at ZO provider offices as of Sept. 16.
Looking closer at the formula’s ingredients, the concentrated serum features four peptide technologies that target signs of aging and support the skin's underlying architecture, per a Sept. 16 press release. Within the concentrate, the Zploy Complex completes the new formula, helping soothe redness and support the skin's protective barrier.
By reinforcing the skin's natural hyaluronic acid production, the serum helps to smooth the appearance of dynamic and static wrinkles, hence its use for post-procedures like filler and Botox. In fact, a 2024 study looking at peptides ruled that this compound shows impressive similarities to Botox—an alternative at the forefront of non-invasive anti-aging effects [1].
The study explained that as Botox injections are invasive and associated with potential adverse effects, it underscores a demand for safer, non-invasive alternatives in clinical practice, like peptides, in particular [1].
When evaluating the product's efficacy, ZO conducted an independent, third-party clinical study consisting of 49 subjects who used the Peptide Facial Refining Concentrate for 12 weeks. Involved in the study were women ages 47-72 with Fitzpatrick skin types I-VI, and working alongside the serum, subjects used gentle cleanser and sunscreen.
The study concluded that 84% saw visibly younger-looking facial geometry, per the release, and 86% saw visible improvement in facial hollow areas. About 92% saw a reduction in the appearance of fine lines.
References:
1- https://www.mdpi.com/2079-9284/11/4/118
